|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announces that it has submitted an application in response to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder. Opioid Use Disorder (OUD), characterized by problematic symptoms of addiction to and withdrawal from opioids, is part of a public health crisis affecting more than 2 million Americans with significant physical, emotional, and cognitive impairment.
Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced that it has received an $830,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant award, received through its wholly-owned subsidiary Nexeon MedSystems Puerto Rico Operations Company Corporation (“NMPROC”), will support the development of novel cloud-based software to improve programming for deep brain stimulation. The NINDS intends to fund $1.5 million over 3 years, subject to annual review and approval, with the remaining funds directed towards clinical evaluation of the software’s performance.
Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced today financial results for the second quarter of 2018. Nexeon completed two additional pre-submission interactions with the United States Food and Drug Administration (“FDA”) to determine the scope of requirements for approval of the Viant™ System for the Parkinson’s disease indication. Nexeon MedSystems Puerto Rico Operations Company Corporation (“NXPROC”), a wholly-owned subsidiary of Nexeon, received notification from the National Institute of Neurological Disorders and Stroke (NINDS) that it is conditionally approved for funding of an U44 Cooperative Agreement Award under the NIH BRAIN Initiative.
NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
Company to Host Conference Call November 20, 2017 4pm CST DALLAS , Nov. 20, 2017 /PRNewswire/ -- Nexeon MedSystems Inc. (OTCQB: NXNN, "Nexeon", "the Company"), is providing shareholders ...